Invitrogen™ CXC-ELR Biosimilar Recombinant Monoclonal Antibody

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °. This antibody can also be cross referenced by the term Lilly patent anti-Pan-ELR+.

CXC chemokines are a subgroup of the chemokine superfamily distinguished by the presence of a C-X-C motif, where X is any amino acid, and they play pivotal roles in immune responses by guiding the migration of leukocytes. A critical subset of these chemokines contains the glutamic acid-leucine-arginine (ELR) motif, which significantly influences angiogenesis and immune cell recruitment. These ELR+ CXC chemokines, including CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8, primarily bind to CXCR1 and CXCR2 receptors. These receptor-ligand interactions activate intracellular signaling pathways essential for neutrophil chemotaxis, tumorigenesis, and wound healing. The structural basis of these interactions and their biological implications, including their roles in pathological conditions such as cancer and inflammatory diseases, have been extensively studied, highlighting their significance in therapeutic targeting.